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AbstrAct
Introduction Acute respiratory distress syndrome (ARDS) 
is a devastating pulmonary condition in the critically 
ill patient. A therapeutic intervention is yet to be found 
that can prevent progression to ARDS. We recently 
demonstrated that the interaction between podoplanin 
expressed on inflammatory alveolar macrophages (iAMs) 
and its endogenous ligand, platelet C-type lectin-like 2 
(CLEC-2), protects against exaggerated lung inflammation 
during a mouse model of ARDS. In this study, we aim to 
investigate the therapeutic use of a crosslinking/activating 
anti-podoplanin antibody (α-PDPN, clone 8.1.1) during 
lipopolysaccharide (LPS)-induced lung inflammation in 
mice.
Methods Intravenous administration of α-PDPN was 
performed 6 hours after intratracheal LPS in wildtype, 
C57Bl/6 mice. Lung function decline was measured by 
pulse oximetry as well as markers of local inflammation 
including bronchoalveolar lavage neutrophilia and cytokine/
chemokine expression. In parallel, alveolar macrophages 
were isolated and cultured in vitro from haematopoietic-
specific podoplanin-deficient mice (Pdpnfl/flVAV1cre+) and 
floxed-only controls treated with or without LPS in the 
presence or absence of α-PDPN.
results Lung function decline as well as alveolar 
neutrophil recruitment was significantly decreased in 
mice treated with the crosslinking/activating α-PDPN in 
vivo. Furthermore, we demonstrate that, in vitro, activation 
of podoplanin on iAMs regulates their secretion of 
proinflammatory cytokines and chemokines.
conclusions These data confirm the importance of the 
CLEC-2–podoplanin pathway during intratracheal (IT)-
LPS and demonstrate the beneficial effect of targeting 
podoplanin during IT-LPS in mice possibly via modulation 
of local cytokine/chemokine expression. Moreover, these 
data suggest that podoplanin-targeted therapies may have 
a beneficial effect in patients at risk of developing ARDS.
IntroductIon
Acute respiratory distress syndrome (ARDS) is 
a life-threatening condition characterised by an 
onset of diagnosis within 7 days of an apparent 
clinical insult, bilateral opacities present on 
chest X-ray and severity defined as ‘mild’ 
(PaO2/FiO2=200–300), ‘moderate’ (PaO2/
FiO2=100–200) or ‘severe’ (PaO2/FiO2<100).
1 
Current treatment strategies are preventative 
with no therapeutic intervention proven to 
prevent the devastating effects of ARDS.2 
Podoplanin is a highly glycosylated cell 
surface protein expressed on alveolar epithe-
lial type I cells and kidney podocytes, and is 
upregulated on various immune cell popu-
lations, including macrophages, during 
inflammation.3 Its endogenous ligand, C-type 
lectin-like 2 (CLEC-2), is an immunoreceptor 
tyrosine-based activation motif-containing cell 
surface receptor, predominantly expressed 
on platelets.4
Alveolar macrophages (AMs) play important 
roles in ARDS, serving as innate cellular defences 
clearing microbes and initiating signals to recruit 
neutrophils and in regulating resolution of the 
ongoing inflammatory response.5 6 In an unchal-
lenged mouse, the predominant AM popula-
tion can be identified as CD11chighCD11bneg/
low using flow cytometry; however, during acute 
lipopolysaccharide (LPS)-induced lung inflam-
mation, an inflammatory population immerges 
in the alveoli that is CD11chighCD11bpos.7 8 Our 
previous data suggest that podoplanin expressed 
only on these CD11chighCD11bpos inflammatory 
alveolar macrophages (iAMs) may interact with 
platelet-expressed CLEC-2 to regulate the local 
inflammatory response.8 Therefore, our aim 
here was to investigate whether therapeutic 
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Key messages
 ► Administration of an anti-podoplanin antibody 
reduces arterial oxygen decline and alveolar 
neutrophilia during intratracheal lipopolysaccharide 
in mice.
 ► Podoplanin expression on inflammatory alveolar 
macrophages regulates their secretion of cytokine/
chemokines in vitro.
 ► Targeting podoplanin may be beneficial in patients 
at risk of developing acute respiratory distress 
syndrome.
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targeting of the CLEC-2–podoplanin pathway is beneficial 
during a mouse model of ARDS.
We demonstrate that administration of a crosslinking/
activating anti-podoplanin antibody (α-PDPN) in vivo, at 
the peak of the acute cytokine and chemokine response, 
significantly reduces lung function decline, with a concom-
itant reduction in alveolar neutrophilia during intratra-
cheal (IT)-LPS. Furthermore, we show that appropriate 
podoplanin expression is required to regulate iAM cytokine 
and chemokine secretion in vitro, suggestive of a potential 
mechanism for the beneficial effect observed in vivo.
Methods
Mice
All mice were maintained in individually ventilated 
cages at the Biomedical Service Unit (BMSU), Univer-
sity of Birmingham, UK. IT procedures were performed 
in accordance with UK laws (Animal (Scientific Proce-
dures) Act 1986) with approval of local ethics committee 
and UK Home Office approval (PPL 40/3741). Pdpnfl/
flVAV1cre+ and floxed-only controls have been described 
previously.8 Wildtype C57Bl/6 mice were purchased from 
Harlan Laboratories (Oxford, UK).
Intratracheal LPs
IT instillations of 40 µg LPS (Escherichia coli O111:B4; 
InvivoGen, France) and MouseOx Plus (Starr Life 
Sciences, USA) were performed as previously described, 
with sequential MouseOX Plus and body weight meas-
urements taken at 1, 2, 3, 4, 6 and 9 days after IT-LPS.9 
Using a second cohort of mice, bronchoalveolar lavage 
(BAL) fluid was extracted post mortem, 48 hours after 
IT-LPS, to measure alveolar neutrophilia, total protein 
and local cytokine/chemokine expression, with lung 
wet:dry weight ratios analysed in a third cohort of mice 
also taken 48 hours after IT-LPS, as previously described.8 
Finally, a fourth cohort of mice was assessed 48 hours 
after IT-LPS for histological assessment by H&E staining. 
Lungs were inflated post mortem with optimum cutting 
temperature compound (Tissue-Tek, The Netherlands) 
in phosphate-buffered saline (PBS) and removed en 
bloc, frozen over dry ice and sections processed as previ-
ously described.8
α-PDPN (clone 8.1.1) (100 µg per mouse) was admin-
istered via intravenous injection at the peak of local 
cytokine and chemokine expression, 6 hours after IT 
instillations,10 and compared with PBS-treated mice. 
Treatments were blinded in non-randomised mice until 
after data analysis. Wildtype C57Bl/6 male mice, aged 
10–14 weeks, were used.
In vitro alveolar macrophage culture
Alveolar macrophages were isolated post mortem via the 
trachea in 10× 1 mL PBS BAL washes from male or female 
Pdpnfl/flVAV1cre+ and floxed-only control mice, aged 8–17 
weeks, as previously described.11 Cells were cultured for 
24 hours either untreated or treated with 0.1 µg/mL LPS 
in the presence or absence of an α-PDPN (clone 8.1.1) 
(10 µg/mL). Secreted cytokines and chemokines were 
measured in the supernatant by Fluorokine MAP Multi-
plex (R&D Systems, Abingdon, UK). Cells were harvested 
in ice-cold 5 mM EDTA in PBS using a 25 cm cell lifter for 
flow cytometry analysis.
statistical analysis
All parameters were analysed using Prism 7 (GraphPad 
Software, USA). Arterial oxygen (O2) saturation, activity 
and weight change were analysed by two-way repeat-
ed-measures analysis of variance (ANOVA), with Sidak’s 
post-test comparisons. For all other data, normality was 
confirmed using a Shapiro-Wilk test and significance 
assessed by one-way ANOVA with Tukey’s multiple 
comparisons test or Student’s t-test as indicated in the 
figure legends along with n numbers. Data are presented 
as box–whisker plots with mean displayed and the range 
of minimum to maximum data points.
resuLts
therapeutic administration of α-PdPn reduces neutrophil 
infiltration and ameliorates lung function decline during It-
LPs
Our previous data suggest that the platelet–CLEC-2–podo-
planin signalling pathway regulates the immune response 
during IT-LPS in mice.8 Therefore, we wanted to investi-
gate the therapeutic potential of targeting this pathway 
in vivo. C57Bl/6 wildtype mice were treated 6 hours 
after administration of IT-LPS with an α-PDPN, which 
induces crosslinking/activation of podoplanin (α-PDPN; 
clone 8.1.1, 100 µg per mouse12 13). α-PDPN-treated mice 
demonstrated a significant reduction in arterial O2 satu-
ration decline after IT-LPS compared with PBS-treated 
controls (P<0.001) (figure 1A). No significant change in 
pulse distention was observed, indicating that the reduc-
tion in O2 saturation was not due to reduced blood flow 
(P=0.516; data not shown).14 This was accompanied by 
significant improvement in animal recovery as assessed 
by increased activity (P=0.043) and weight gain (P=0.007) 
in α-PDPN-treated mice (figure 1A).
Histological assessment of lung tissue at peak neutro-
philia (48 hours after IT-LPS) demonstrated reduced 
neutrophil infiltration in α-PDPN-treated animals 
(figure 1B). This was quantified by analysing BAL neutro-
philia, which revealed a significant reduction in mice 
treated with α-PDPN (figure 1C). Total BAL protein 
48 hours after IT-LPS was also reduced in α-PDPN-treated 
mice compared with PBS-treated controls (figure 1C). 
However, no change in lung wet:dry weight ratio was 
observed 48 hours after IT-LPS in animals treated with 
α-PDPN compared with controls (figure 1C).
The level of the acute inflammatory cytokine, inter-
leukin (IL)-6, in BAL fluid was also significantly reduced 
in α-PDPN-treated mice 48 hours after IT-LPS (figure 1D), 
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Figure 1 Therapeutic administration of an anti-podoplanin antibody (α-PDPN) is beneficial during a mouse model of 
acute respiratory distress syndrome. (A) Sao2 (P<0.001) and activity (P=0.043) were measured by MouseOx Plus, as well as 
cumulative weight change of wildtype mice (P=0.007) given intravenous phosphate-buffered saline (PBS) or α-PDPN 6 hours 
after intratracheal (IT) instillation of lipopolysaccharide (LPS). Mice were monitored for 9 days after IT-LPS (intravenous 
PBS n=8, intravenous α-PDPN n=7; mean±SEM). Two-way repeated-measures analysis of variance was performed with 
Sidak’s multiple comparisons test. (B) H&E staining of lungs from wildtype mice given α-PDPN 6 hours after IT instillation of 
LPS compared with controls (n=4). Bar, 100 µm. (C) Bronchoalveolar lavage (BAL) neutrophilia, total BAL protein and lung 
wet:dry weight ratio were measured 48 hours after IT-LPS in wildtype mice given intravenous PBS or α-PDPN 6 hours after 
IT instillation of LPS (BAL neutrophilia and protein n=10; wet:dry ratio n=6). Student’s t-tests were performed. (D) Expression 
of cytokines/chemokines in BAL were measured 48 hours after IT-LPS in wildtype mice given intravenous PBS or α-PDPN 
6 hours after IT instillation of LPS (n=6). Student’s t-tests were performed. *P<0.05; **P<0.01. IL-6, interleukin-6;  
TNFα, tumour necrosis factor alpha.
further demonstrating the anti-inflammatory effect of 
α-PDPN therapy during this mouse model.
Taken together, these data confirm the importance 
of the CLEC-2–podoplanin pathway during IT-LPS and 
demonstrate the beneficial effect of targeting podo-
planin during IT-LPS in mice.
Podoplanin expression on in vitro-generated inflammatory 
alveolar macrophages regulates their cytokine/chemokine 
release
Having observed a beneficial effect of crosslinking/
activating podoplanin during IT-LPS, we next consid-
ered the possible mechanism for this effect. Our 
previous data suggest that CLEC-2 on platelets regulates 
the immune response during IT-LPS via podoplanin 
specifically expressed on iAMs.8 Therefore, murine AMs 
were isolated following BAL washes and cultured in vitro 
for 24 hours to generate an inflammatory phenotype, as 
previously described.11 Culture-induced iAMs were iden-
tified as F4/80+CD11c+CD11b+ cells using flow cytometry 
(online supplementary figure 1A). Although variable, 
the percentage of iAMs present after 24 hours of culture 
did not alter significantly between conditions (P=0.113; 
online supplementary figure 1B).
The inflammatory phenotype of the iAMs was first 
confirmed by high expression of the M1 marker, inducible 
nitric oxide synthase (iNOS),15 compared with low expres-
sion of the M2 marker, early growth response protein 2 
(Erg2)16 (figure 2A and B, respectively; gating strategy is 
indicated in online supplementary figure 1A). In untreated 
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Figure 2 Inducible nitric oxide synthase (iNOS), early growth response protein 2 (Erg2) and podoplanin expression 
on in vitro-generated inflammatory alveolar macrophages. Bronchoalveolar lavage (BAL) alveolar macrophages (AMs) 
isolated from Pdpnfl/flVAV1cre+ or floxed-only controls (wildtype) were cultured for 24 hours and treated with or without 
lipopolysaccharide (LPS), in the presence or absence of anti-podoplanin antibody (α-PDPN). (A) Cell surface expression of 
iNOS, (B) Erg2 and (C) podoplanin assessed by flow cytometry and compared with AMs isolated without culturing (ex vivo). 
One-way analysis of variance was performed on each parameter with Tukey’s multiple comparisons test (n=5–6).   
*P<0.05; **P<0.01; ***P<0.001. N.D., not determined.
conditions and in line with our in vivo data,8 podoplanin is 
also expressed on culture-generated iAMs (57.5%±11.2%) 
compared with AMs isolated straight ex vivo (11.7%±8.4%) 
derived from wildtype mice (figure 2C).
Constitutive deletion of podoplanin is lethal in murine 
models17; therefore, to investigate the function of podo-
planin on these macrophages, we used a haematopoi-
etic-specific podoplanin-deficient mouse strain (Pdpnfl/
flVAV1cre+8). As expected, significantly lower podoplanin 
expression is observed on cultured iAMs isolated from 
Pdpnfl/flVAV1cre+ mice compared with wildtype controls 
(31.2%±8.7%) (figure 2C).
The addition of LPS (0.1 µg/mL) to cultures for 
24 hours did not significantly alter expression of iNOS, 
Erg2 or podoplanin on iAMs derived from Pdpnfl/
flVAV1cre+ or wildtype controls (figure 2A,B). Cultured 
AMs were also treated with the α-PDPN antibody for 
24 hours to induce crosslinking/activation of podoplanin 
in the presence or absence of LPS (α-PDPN; clone 8.1.1, 
10 µg/mL12 13). A significant reduction in iNOS expres-
sion was observed on iAMs in α-PDPN-treated cells 
derived from wildtype mice (P=0.023), which remained 
consistent in the presence of LPS (figure 1A). Conversely, 
α-PDPN treatment did not alter iNOS expression in iAMs 
derived from Pdpnfl/flVAV1cre+ mice (P=0.954).
The functional relevance of podoplanin expression 
and/or α-PDPN treatment was assessed by measuring 
inflammatory cytokines/chemokines in the media of 
24hour-cultured AMs. All data are presented normalised 
to the percentage of iAMs present in the culture. Expres-
sion of IL-6, chemokine (C-X-C motif) ligand (CXCL)2, 
CXCL1 and tumour necrosis factor alpha (TNFα) were 
not significantly altered in iAMs derived from wildtype 
mice when cultured with LPS compared with LPS-free 
conditions (figure 3). In addition, α-PDPN treatment did 
not significantly affect these levels. Conversely, expression 
of IL-6, CXCL2 and TNFα were significantly increased in 
cultured cells derived from Pdpnfl/flVAV1cre+ mice when 
cultured in the presence of LPS compared with LPS-free 
conditions (19.1-fold, 7.4-fold and 8.1-fold, respec-
tively) (figure 3A,B,D). Addition of α-PDPN significantly 
reduced these levels back to LPS-free levels, suggesting 
that α-PDPN is only effective in hyper-responsive envi-
ronments even when podoplanin expression is reduced. 
Furthermore, LPS-treated Pdpnfl/flVAV1cre+-derived iAMs 
express significantly higher levels of CXCL2 and TNFα 
compared with LPS-treated wildtype iAMs (2.0-fold and 
2.5-fold, respectively) (figure 3B and D, respectively).
Together, these data suggest that podoplanin expressed 
on iAMs regulates their release of proinflammatory cyto-
kines and chemokines in culture.
dIscussIon
The principal findings of this study are that (1) targeting 
podoplanin in vivo limits acute lung inflammation, 
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Figure 3 Podoplanin expression on inflammatory alveolar macrophages (iAMs) regulates their immune function in vitro. 
Expression of (A) interleukin-6 (IL-6), (B) CXCL2, (C) CXCL1 and (D) tumour necrosis factor alpha (TNFα) in the media of in 
vitro-generated iAMs measured after 24 hours of culture, treated with or without LPS, in the presence or absence of anti-
podoplanin antibody (α-PDPN) (n=5). Data were normalised to the percentage of iAMs present in the culture and presented in 
arbitrary units (au). One-way analysis of variance was performed with Tukey’s multiple comparisons test. *P<0.05; **P<0.01; 
***P<0.001.
improving animal welfare during IT-LPS, and (2) podo-
planin expressed on in vitro-generated inflammatory alve-
olar macrophages regulates their cytokine/chemokine 
secretion.
Our previous work suggested that the interaction 
between platelet–CLEC-2 and podoplanin expressed on 
iAMs limits excessive lung inflammation during IT-LPS 
in mice.8 Specifically, the data ruled out the contribution 
of other lung resident podoplanin-expressing haemato-
poietic cells, alveolar type I cells and lymphatic cells by 
the use of conditional knockout mouse models in vivo. 
Together with the data presented here, our findings 
suggest that expression and/or activation of podoplanin 
on iAMs is required for appropriate cytokine/chemokine 
release from these cells, which influences neutrophil 
recruitment and, in turn, lung function during IT-LPS. 
However, there remains no direct evidence for this or for 
the direct platelet–CLEC-2-mediated activation of podo-
planin on iAMs. Delineating when and how this happens 
during IT-LPS will be the focus of future studies.
An increase in BAL neutrophilia and total protein was 
observed in α-PDPN-treated animals during IT-LPS but 
not lung wet:dry lung weight. This is indicative of the 
α-PDPN treatment reducing lung inflammation without 
affecting the increase in lung permeability observed 
following IT-LPS. These results were similar to those 
observed using multiple conditional CLEC-2/podo-
planin-deficient mouse strains 48 hours after IT-LPS,8 
indicative of this pathway’s major role in protecting 
against excessive pulmonary inflammation rather than 
affecting barrier function in this model.
There are limitations to this study. First is the assump-
tion that the iAMs generated by in vitro culturing 
relate directly to those observed in the alveolar space 
in vivo following IT-LPS. Using bone marrow chimeras 
combined with intranasal LPS administration, the origin 
of iAMs has been described to be from both tissue/alve-
olar resident and blood precursors.7 Therefore, we chose 
to generate iAMs directly from alveolar resident AMs as 
previously reported.11 However, the composition of AM 
subpopulations in vivo is diverse and dynamic, especially 
during inflammation,18 and thus whether the culture-gen-
erated iAMs truly represent those present during IT-LPS 
remains speculative. It will therefore be important in 
future studies to fully characterise these podoplanin-ex-
pressing iAMs beyond the parameters tested in this study 
and also use bloodborne AM precursors to investigate the 
role of podoplanin on this subpopulation of cells.
Second, we observed only a reduction in podoplanin 
expression in Pdpnfl/flVAV1cre+-derived iAMs, possibly 
due to the mixed progenitor population, which contrib-
utes to AMs in adult mice as previously reported.19 Ideally, 
a complete knockout of podoplanin is required to fully 
assess its function; however, global deletion of podo-
planin is embryonic lethal in mouse models.17 Given that 
an approximately 50% reduction in protein expression 
still had a significant effect on CXCL2 and TNFα expres-
sion is supportive of the importance of podoplanin in 
this in vitro system.
Finally, we only used one in vivo model of ARDS to 
assess the therapeutic targeting of podoplanin. IT-LPS 
predominantly reproduces the acute neutrophilic 
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inflammatory responses that occur during ARDS in 
patients. Other aspects such as severe endothelial and 
epithelial injury as well as repair with fibrosis are less 
apparent or absent in this model.20 It will therefore be 
of paramount importance to test the α-PDPN in other 
models of ARDS.
In conclusion, this study demonstrates that thera-
peutic administration of an α-PDPN is beneficial during 
a mouse model of ARDS in vivo. This may be via acti-
vation of podoplanin expressed on iAMs, altering local 
cytokine/chemokine expression, which in turn regu-
lates neutrophil recruitment. Targeting podoplanin may 
therefore represent a novel avenue for future therapeu-
tics in patients at risk of developing ARDS.
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